Why the study?
Genome-wide association studies link CVD with CHIP, particularly TET2 mutations, prompting the need to determine whether self-organizing cardiac organoids can model cardiovascular CHIP and identify potential therapeutics.
Do selected drugs like Lanatoside C reduce inflammation and improve cardiac function in a TET2 cardiac-CHIP organoid model?
Do selected drugs like Lanatoside C reduce inflammation and improve cardiac function in a TET2 cardiac-CHIP organoid model?
Answers are grounded in this paper and cite their sources.
A novel TET2 cardiac-CHIP organoid model demonstrates that Lanatoside C can rescue CHIP-induced cardiac inflammation, fibrosis, and apoptosis, highlighting its potential for repurposing in CHIP-related cardiovascular disease.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied TET2-mutant cardiovascular CHIP. Lanatoside C vs. Vehicle was evaluated on Inflammation, fibrosis, apoptosis, and cardiac contractile function.
Synapse has enriched 10 related papers. Consider them for comparative context: